Cantargia AB (FRA:7V3)
€ 0.1345 -0.0033 (-2.39%) Market Cap: 28.59 Mil Enterprise Value: 23.41 Mil PE Ratio: 0 PB Ratio: 6.87 GF Score: 38/100

Q1 2023 Cantargia AB Earnings Call Transcript

May 23, 2023 / 08:00AM GMT
GÃ;ran Forsberg
Cantargia AB - CEO

¶ -

It's a pleasure to present Cantargia's quarter one report. It's been a good start of the year for Cantargia. And during this period or directly after the period, we had a really good news flow. And we started out strongly by presenting new data in triple-negative breast cancer, which was part of the Phase I part of the early-in phase of a randomized trial called TRIFOUR, and we will have a quick look at those data later on. But what's noted is that directly afterwards, the first patient started treatment in randomized phase of trials and recruitment is now ongoing.

In our second program, CAN10, we also made some progress during the period, where GLP tox study was successfully completed and, later on, we could then send in the application to start the first clinical trial. And we will come back with timelines around that.

We also made a change to our Chief Financial Officer position, with Bengt Jöndell winding down and Patrik Renblad starting out. And what I'm going to say here is that we're just in the middle of the transition period

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot